Phaseline

Targets › PRKD3

PRKD3 (Serine/threonine-protein kinase D3): drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 1, 2 Phase 2; Oncology; next expected readout May 2029.

Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress (By similarity). (UniProt, O94806)

Open in Phaseline: the race on PRKD3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisMidostaurin
Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor
FLT3, KIT, PDGFRB, PDGFRA, PRKD3Phase 2FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid LeukemiaMay 2029

Conditions

Acute Myeloid Leukemia (3) FLT3-mutated Acute Myeloid Leukemia (1) AML/MDS (1)

Modalities

small molecule (1)

Companies

Novartis (1)

Related targets

FLT3 (1) KIT (1) PDGFRB (1) PDGFRA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.